Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures
Viktor Farkas, Barbara Steinborn, J Robert Flamini, Ying Zhang, Nancy Yuen, Simon Borghs, Ali Bozorg, Tony Daniels, Paul Martin, Hannah C Carney, Svetlana Dimova, Ingrid E Scheffer
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019
OBJECTIVE: To evaluate efficacy and tolerability of adjunctive lacosamide in children and adolescents with uncontrolled focal (partial-onset) seizures. METHODS: In this double-blind trial (SP0969; NCT01921205), patients (age ≥4-<17 years) with uncontrolled focal seizures were randomized (1:1) to adjunctive lacosamide/placebo. After a 6-week titration, patients who reached the target dose range for their weight (<30 kg: 8-12 mg/kg/d oral solution; ≥30-<50 kg: 6-8 mg/kg/d oral solution; ≥50 kg: 300-400 mg/d tablets) entered a 10-week maintenance period. The primary outcome was change in focal seizure frequency per 28 days from baseline to maintenance. RESULTS: Three hundred forty-three patient..View full abstract
Supported by UCB Pharma, Brussels, Belgium.